<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006354</url>
  </required_header>
  <id_info>
    <org_study_id>2011-KAEK-25 2016/22-06</org_study_id>
    <nct_id>NCT03006354</nct_id>
  </id_info>
  <brief_title>nHFOV Versus nCPAP in Transient Tachypnea of the Newborn</brief_title>
  <official_title>Nasal High Frequency Oscillatory Ventilation Versus Nasal Continuous Positive Airway Pressure in Late-Preterm and Term Infants With Transient Tachypnea of the Newborn: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Yüksek İhtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Yüksek İhtisas Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, randomised clinical trial the investigators aim to assess if nasal high&#xD;
      frequency oscillatory ventilation (nHFOV) could be used as the primary modality of&#xD;
      respiratory support in late preterm and term infants with transient tachypnea of the newborn&#xD;
      requiring non-invasive ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Non-invasive High Frequency Oscillatory Ventilation (nHFOV), aims to combine the&#xD;
      efficacy of high frequency ventilation with the gentleness of non-invasive support and&#xD;
      current evidence suggests that nHFOV may be superior to other non-invasive modes in terms of&#xD;
      supporting alveolar ventilation. There are now several published neonatal studies of nHFOV&#xD;
      therapy as a rescue mode even in the premature infants; however to date no studies have been&#xD;
      published on the efficacy of nHFOV as a primary mode of non-invasive support. The&#xD;
      investigators aim to assess the efficacy of nHFOV in late-preterm and term infants with&#xD;
      transient tachypnea of the newborn as the primary mode of non-invasive support.&#xD;
&#xD;
      METHOD: The investigators propose to test the effectiveness of nHFOV in late-preterm and term&#xD;
      neonates with transient tachypnea of the newborn (TTN) with a Silverman Score of 4 or above&#xD;
      on admission who require non-invasive respiratory support. Nasal high frequency oscillatory&#xD;
      ventilation may be effective in decreasing duration of non-invasive respiratory support and&#xD;
      total oxygen therapy (H1 hypotheses).&#xD;
&#xD;
      The current literature estimates the incidence of transient tachypnea of the newborn to be&#xD;
      5.7 per 1000 births. Assuming that a 5% difference of the primary outcome between the groups&#xD;
      is significant, when the alpha value is set at 0.05 and power of the study at 80%, 220&#xD;
      infants must be recruited for each arm (nCPAP and nHFOV) under investigation.&#xD;
&#xD;
      Chest X-ray, complete blood count, C-reactive protein and capillary blood gas analysis (as&#xD;
      per unit protocol) will be obtained upon admission to the neonatal intensive care unit. A&#xD;
      Silverman Score will be obtained for each participant upon admission and those with a score&#xD;
      of 4 and above will be supported with one of the methods (with randomization).&#xD;
&#xD;
      Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be&#xD;
      adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep&#xD;
      preductal sPO2 between %90-95. Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to&#xD;
      keep preductal sPO2 between %90-95. Failure of the primary mode is defined as FiO2&#xD;
      requirement of &gt;%60, capillary blood gas obtained at the 4th hour of therapy showing pH&lt;7.20&#xD;
      or pCO2&gt;65 cmH2O. When nCPAP or nHFOV failure occurs, nasal intermittent positive pressure&#xD;
      ventilation (nIPPV) will be applied as a rescue therapy with the following settings:&#xD;
      Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10&#xD;
      L/min, FiO2:adjusted to keep preductal sPO2 between %90-95. If the rescue mode fails, the&#xD;
      infant will be intubated and conventional mechanical ventilation will be initiated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to cessation of non-invasive positive pressure respiratory support</measure>
    <time_frame>72 hours</time_frame>
    <description>Cessation of nasal flaring, grunting and chest wall retractions (Silverman Score of 0) are indicators of readiness for discontinuation non-invasive positive pressure respiratory support.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of supplemental oxygen</measure>
    <time_frame>120 hours</time_frame>
    <description>Total duration of oxygen support of &gt;21%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge from hospital</measure>
    <time_frame>120 hours</time_frame>
    <description>Discharge time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pneumothorax</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of pneumothoraces requiring tube thoracostomy in each group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Transient Tachypnea of the Newborn</condition>
  <arm_group>
    <arm_group_label>nHFOV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.&#xD;
Failure is defined as FiO2 requirement of &gt;%60, capillary blood gas obtained at the 4th hour of therapy showing pH&lt;7.20 or pCO2&gt;65 cmH2O.&#xD;
When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.&#xD;
Failure is defined as FiO2 requirement of &gt;%60, capillary blood gas obtained at the 4th hour of therapy showing pH&lt;7.20 or pCO2&gt;65 cmH2O.&#xD;
When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nHFOV</intervention_name>
    <description>Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs</description>
    <arm_group_label>nHFOV</arm_group_label>
    <other_name>nasal high frequency oscillatory ventilation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nCPAP</intervention_name>
    <description>Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs</description>
    <arm_group_label>nCPAP</arm_group_label>
    <other_name>nasal continuous positive airway pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age at birth between 34 and 42 weeks of gestation&#xD;
&#xD;
          -  Admission to Bursa Yüksek Ihtisas Teaching Hospital, NICU during the first 24 hours of&#xD;
             life&#xD;
&#xD;
          -  Diagnosis of transient tachypnea of the newborn (TTN) within the first 24 hours of&#xD;
             life&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gestational age at birth less than 34 weeks or greater than 42 weeks at birth&#xD;
&#xD;
          -  Chest X-ray or lung ultrasound finding indicating another respiratory disorder&#xD;
&#xD;
          -  Additional infant diagnosis of major cardiac disease&#xD;
&#xD;
          -  Additional infant diagnosis of major pulmonary disease other than TTN&#xD;
&#xD;
          -  Additional infant diagnosis of major congenital anomaly with potential to affect&#xD;
             respiratory status in the neonatal period&#xD;
&#xD;
          -  Additional infant diagnosis of infectious disease process potentially affecting&#xD;
             respiratory status in the neonatal period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet N Cizmeci, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Bursa Yuksek Ihtisas Teaching Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emre Baldan, M.D</last_name>
    <phone>+905456467876</phone>
    <email>emrebaldan@e-mail.com.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ipek Guney Varal, M.D</last_name>
    <phone>+905323413389</phone>
    <email>ibettyg@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Health Sciences, Bursa Yuksek Ihtisas Teaching Hospital</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet N Cizmeci, M.D</last_name>
      <phone>+905056576539</phone>
      <email>nevzatcizmeci@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ipek G Varal, M.D</last_name>
      <phone>+905323413389</phone>
      <email>ibettyg@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Fischer HS, Bohlin K, Bührer C, Schmalisch G, Cremer M, Reiss I, Czernik C. Nasal high-frequency oscillation ventilation in neonates: a survey in five European countries. Eur J Pediatr. 2015 Apr;174(4):465-71. doi: 10.1007/s00431-014-2419-y. Epub 2014 Sep 18.</citation>
    <PMID>25227281</PMID>
  </results_reference>
  <results_reference>
    <citation>De Luca D, Dell'Orto V. Non-invasive high-frequency oscillatory ventilation in neonates: review of physiology, biology and clinical data. Arch Dis Child Fetal Neonatal Ed. 2016 Nov;101(6):F565-F570. doi: 10.1136/archdischild-2016-310664. Epub 2016 Jun 28.</citation>
    <PMID>27354382</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bursa Yüksek İhtisas Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Mehmet Nevzat Çizmeci</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>high frequency oscillatory ventilation</keyword>
  <keyword>newborn</keyword>
  <keyword>noninvasive ventilation</keyword>
  <keyword>transient tachypnea of the newborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachypnea</mesh_term>
    <mesh_term>Transient Tachypnea of the Newborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

